Scarica l'app Stockscreener
32.60
1.78%
-0.59
Pre-mercato:
32.19
-0.41
-1.26%
Precedente Chiudi:
$33.19
Aprire:
$33.255
Volume 24 ore:
1.51M
Relative Volume:
0.97
Capitalizzazione di mercato:
$5.18B
Reddito:
$803.07M
Utile/perdita netta:
$-358.81M
Rapporto P/E:
-13.36
EPS:
-2.44
Flusso di cassa netto:
$-374.21M
1 W Prestazione:
+2.23%
1M Prestazione:
+1.46%
6M Prestazione:
-31.09%
1 anno Prestazione:
-28.29%
Intervallo 1D:
$32.25
$33.54
Intervallo di 1 settimana:
$30.99
$33.54
Portata 52W:
$30.23
$52.34
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
32.60 | 5.18B | 803.07M | -358.81M | -374.21M | -2.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Spinal Muscular Atrophy Market Overall Study Report 2025-2032 | - openPR
Spinal Muscular Atrophy Pipeline 2024: Key Companies, MOA, ROA, - openPR
ARK Investment Management LLC Sells 359,009 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $60.00 Consensus Target Price from Analysts - MarketBeat
Investor Network: Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus - MSN
FY2026 Earnings Estimate for IONS Issued By Leerink Partnrs - MarketBeat
Intellia: Balancing in vivo risk with validated targets - BioCentury
Ionis Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Equities Analysts Set Expectations for IONS Q1 Earnings - MarketBeat
Leerink upgrades Ionis to outperform, cites Angelman drug - MSN
Ionis to present at upcoming investor conferences - Post Register
5 Undervalued Stocks That Crushed Q4 Earnings - Morningstar
Ionis Pharmaceuticals’ SWOT analysis: RNA pioneer’s stock faces pivotal year - Investing.com
Ionis Pharmaceuticals EVP Patrick O'Neil sells $39,046 in stock By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Officer Sells Shares - TradingView
The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis - Nasdaq
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $45.00 by Analysts at BMO Capital Markets - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Issues Earnings Results - MarketBeat
Ionis Pharmaceuticals Reports Strong 2024 Results - TipRanks
Ionis Pharmaceuticals targets multibillion-dollar revenue potential with TRYNGOLZA and new launches - MSN
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James - Yahoo Finance
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control - BioSpace
Ionis Earnings: Tryngolza Commercial Launch Underway; Shares Very Undervalued - Morningstar
Ionis posts Q4 beat as revenue base widens - MSN
Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel - MSN
What Analysts Are Saying About Ionis Pharmaceuticals Stock - Benzinga
Ionis presents new data on HAE drug donidalorsen By Investing.com - Investing.com Nigeria
BESREMi Achieves Strong Market Growth Amid Rising Demand for Polycythemia Vera Treatment - GlobeNewswire Inc.
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Continues to Expand Its Cardiology and Neurology Portfolio, Supporting Narrow Moat - Morningstar
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2024 Earnings Call Transcript - Insider Monkey
Ionis stock target cut to $60 by Raymond James - Investing.com India
Ionis presents new data on HAE drug donidalorsen - Investing.com
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Simply Wall St
Can This New HAE Treatment Transform Patient Care? Key Clinical Data Revealed - StockTitan
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... - Yahoo Finance
Ionis Pharmaceuticals: Q4 Earnings Snapshot - The Advocate
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - MSN
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Ionis Pharmaceuticals: Positive Sentiment in Earnings Call - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Stock Quotes, Forecast and News Summary - Benzinga
Stifel cuts Ionis Pharmaceuticals target to $38, maintains Hold - Investing.com India
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval (IONS) - Seeking Alpha
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales - AOL
Ionis Pharma Beats Expectations for Q4 - MSN
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts - Investing.com
Earnings call transcript: Ionis Pharmaceuticals Q4 2024 surpasses forecasts By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.13%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):